Trial Profile
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms BOSTON
- Sponsors Karyopharm Therapeutics
- 08 Jan 2024 According to a Karyopharm Therapeutics media release, Top-Line Data Readouts Expected in 2H 2024 and 2025
- 01 Dec 2023 Results of a post-hoc analysis assessing efficacy, safety, and QoL of patients treated with reduced doses of selinexor in BOSTON compared to those with no dose reduction in this trial published in the Clinical Lymphoma, Myeloma & Leukemia
- 26 Sep 2023 According to a Karyopharm Therapeutics media release,the Subgroup Data and Updated Results of this Trial will be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece.